Opinion|Videos|August 22, 2024
Updated Data from EHA 2024: Transplant Ineligible NDMM
Author(s)Rafael Fonseca, MD, Binod Dhakal, MD, MS
Multiple myeloma experts analyze recent developments in transplant-ineligible newly diagnosed multiple myeloma treatment, focusing on the latest updates presented at EHA 2024 and their potential impact on patient care.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How does the updated data from the trials below impact transplant ineligible NDMM?
- MAIA
- BENEFIT
- IMROZ
Advertisement
Related to this article
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
The FDA’s decision on iberdomide is a “landmark approval” for those with multiple myeloma, according to Surbhi Sidana, MD.
Full results from the phase 3 CERVINO trial assessing etentamig in relapsed/refractory multiple myeloma will be shared at the 23rd IMS Annual Meeting.
Matthew Matasar, MD, reflected on how quickly oncology has moved from skepticism to nimble adoption of AI, and what he expects from the field going forward.
Advertisement
Advertisement
Trending on CancerNetwork
1
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
2
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
3
Secondary T-Cell Malignancies: Identifying and Counseling After CAR T-Cell Therapy
4
PALOMA-2 Shows Improved Survival vs Historical IV Amivantamab Data
5